$RCKT News

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4

Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol

Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target

Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript

Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data - Slideshow

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?

Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock

Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target

Needham Upgrades Rocket Pharmaceuticals to Buy, Announces $9 Price Target

Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial

Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Rocket Pharmaceuticals Aligned With FDA on Continued Enrollment and Dosing and key elements of Phase 2 trial of RP-A501 for Danon disease